Amneal Pharmaceuticals, Inc.
AMRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2,793,957 | $2,393,607 | $2,212,304 | $2,093,669 |
| % Growth | 16.7% | 8.2% | 5.7% | – |
| Cost of Goods Sold | $1,773,519 | $1,529,738 | $1,420,843 | $1,324,696 |
| Gross Profit | $1,020,438 | $863,869 | $791,461 | $768,973 |
| % Margin | 36.5% | 36.1% | 35.8% | 36.7% |
| R&D Expenses | $190,714 | $194,750 | $208,658 | $209,563 |
| G&A Expenses | $442,036 | $417,275 | $382,900 | $0 |
| SG&A Expenses | $476,436 | $429,675 | $399,700 | $365,504 |
| Sales & Mktg Exp. | $34,400 | $12,400 | $16,800 | $0 |
| Other Operating Expenses | $103,962 | $35,070 | $278,031 | $41,190 |
| Operating Expenses | $771,112 | $659,495 | $886,389 | $616,257 |
| Operating Income | $249,326 | $204,374 | -$94,928 | $152,716 |
| % Margin | 8.9% | 8.5% | -4.3% | 7.3% |
| Other Income/Exp. Net | -$304,339 | -$244,644 | -$153,199 | -$121,350 |
| Pre-Tax Income | -$55,013 | -$40,270 | -$248,127 | $31,366 |
| Tax Expense | $18,863 | $8,452 | $6,662 | $11,196 |
| Net Income | -$116,886 | -$83,993 | -$129,986 | $10,624 |
| % Margin | -4.2% | -3.5% | -5.9% | 0.5% |
| EPS | -0.38 | -0.48 | -0.86 | 0.07 |
| % Growth | 20.8% | 44.2% | -1,328.6% | – |
| EPS Diluted | -0.38 | -0.48 | -0.86 | 0.07 |
| Weighted Avg Shares Out | 308,978 | 174,985 | 150,944 | 148,922 |
| Weighted Avg Shares Out Dil | 308,978 | 176,136 | 150,944 | 151,821 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $158,377 | $0 |
| Interest Expense | $258,595 | $210,629 | $158,377 | $136,325 |
| Depreciation & Amortization | $236,191 | $229,400 | $240,175 | $233,406 |
| EBITDA | $439,773 | $500,782 | $440,208 | $401,097 |
| % Margin | 15.7% | 20.9% | 19.9% | 19.2% |